Tag: Allergies: Food
Recommendations Developed to Prepare Patients for Oral Immunotherapy
76 statements specific to OIT preparatory procedures were included, as well as 71 on the consent information form
AAAAI: Omalizumab Superior to Placebo for Those With Multiple Food Allergies
16 weeks of omalizumab superior for increasing reaction threshold for peanut and other food allergens
Expanded Use of Xolair to Treat Food Allergies Approved by the FDA
Xolair is not meant to substitute for emergency anaphylaxis medications such as the EpiPen
ACAAI: Parents, Patients Offer Theories on Causes/Origins of Food Allergies
Parents and adult patients with food allergy believe diet, genetics, family history, infection are linked to food allergy development
Sublingual Immunotherapy Safe, Effective for Treating Toddlers’ Peanut Allergy
Improved outcomes seen with younger age at initiation
Gut Microbiome May Predict Later Peanut Allergies
Infants who eventually developed peanut allergies had lower gut microbiome diversity during their early years
Peanut Oral Immunotherapy Effective for Children Under 12 Months
OIT can safely induce desensitization to peanuts in children younger than 12 months of age
Even Transient Food Allergy in Infancy Impacts Later Lung Function
For allergies at age 1 year, lung function deficits and asthma seen at 6 years
More Parents Are Introducing Peanuts Early
Guideline awareness and primary care provider encouragement are significant drivers of early introduction
Provider Awareness and Knowledge of Alpha-Gal Syndrome Limited
Suspected cases mainly occur in counties within the Southern, Midwestern, and Mid-Atlantic U.S. Census Bureau regions
